David Klonoff, M.D., a board-certified endocrinologist, has been medical director of the DRI since 2000. After graduating from UCSF Medical School, he completed five years of postgraduate training at UCLA Hospital and UCSF hospitals. He has been instrumental in research into an artificial pancreas, continuous and noninvasive glucose monitors, novel hemoglobin A1c assays, new types of insulin pumps, alternate routes of insulin administration and digital health.
Dr. Klonoff received the American Diabetes Association Outstanding Physician Clinician Award in 2019. This international award honors meritorious contributions to diabetes clinical practice. He received an FDA Director’s Special Citation Award in 2010 for outstanding contributions related to diabetes technology. Dr. Klonoff coined the term “diabetes technology” and was the lead investigator on the landmark ASPIRE 2 study, which was the first multi-center outpatient study of a commercial artificial pancreas product.
He is the founding editor-in-chief of Journal of Diabetes Science and Technology and has authored more than 200 publications in PubMed-indexed journals, plus many research abstracts and textbook chapters. Dr. Klonoff has been a United States Army civilian medical officer in physiological monitoring at Fort Detrick, Md.; an advisor to NASA, the United States Air Force and the Centers for Disease Control and Prevention; and a visiting professor at Tokyo University of Agriculture and Technology. He has spoken before the United States Congressional Diabetes Caucus, participated in the White House Health and Cybersecurity Roundtable and presented at the European Parliament.